Cargando…
Rationale for using centralized transduction inhibition assays in three phase 3 rAAV gene therapy clinical trials
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Gene & Cell Therapy
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585313/ https://www.ncbi.nlm.nih.gov/pubmed/37868207 http://dx.doi.org/10.1016/j.omtm.2023.101119 |
| _version_ | 1785122928324509696 |
|---|---|
| author | Schulz, Martin Bashirians, George Cheng, Seng H. Levy, Daniel I. Lundie, Mark Wilcox, Lisa Winburn, Ian Somanathan, Suryanarayan |
| author_facet | Schulz, Martin Bashirians, George Cheng, Seng H. Levy, Daniel I. Lundie, Mark Wilcox, Lisa Winburn, Ian Somanathan, Suryanarayan |
| author_sort | Schulz, Martin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10585313 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | American Society of Gene & Cell Therapy |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105853132023-10-20 Rationale for using centralized transduction inhibition assays in three phase 3 rAAV gene therapy clinical trials Schulz, Martin Bashirians, George Cheng, Seng H. Levy, Daniel I. Lundie, Mark Wilcox, Lisa Winburn, Ian Somanathan, Suryanarayan Mol Ther Methods Clin Dev Editorial American Society of Gene & Cell Therapy 2023-10-11 /pmc/articles/PMC10585313/ /pubmed/37868207 http://dx.doi.org/10.1016/j.omtm.2023.101119 Text en © 2023 Pfizer, Inc https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Editorial Schulz, Martin Bashirians, George Cheng, Seng H. Levy, Daniel I. Lundie, Mark Wilcox, Lisa Winburn, Ian Somanathan, Suryanarayan Rationale for using centralized transduction inhibition assays in three phase 3 rAAV gene therapy clinical trials |
| title | Rationale for using centralized transduction inhibition assays in three phase 3 rAAV gene therapy clinical trials |
| title_full | Rationale for using centralized transduction inhibition assays in three phase 3 rAAV gene therapy clinical trials |
| title_fullStr | Rationale for using centralized transduction inhibition assays in three phase 3 rAAV gene therapy clinical trials |
| title_full_unstemmed | Rationale for using centralized transduction inhibition assays in three phase 3 rAAV gene therapy clinical trials |
| title_short | Rationale for using centralized transduction inhibition assays in three phase 3 rAAV gene therapy clinical trials |
| title_sort | rationale for using centralized transduction inhibition assays in three phase 3 raav gene therapy clinical trials |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585313/ https://www.ncbi.nlm.nih.gov/pubmed/37868207 http://dx.doi.org/10.1016/j.omtm.2023.101119 |
| work_keys_str_mv | AT schulzmartin rationaleforusingcentralizedtransductioninhibitionassaysinthreephase3raavgenetherapyclinicaltrials AT bashiriansgeorge rationaleforusingcentralizedtransductioninhibitionassaysinthreephase3raavgenetherapyclinicaltrials AT chengsengh rationaleforusingcentralizedtransductioninhibitionassaysinthreephase3raavgenetherapyclinicaltrials AT levydanieli rationaleforusingcentralizedtransductioninhibitionassaysinthreephase3raavgenetherapyclinicaltrials AT lundiemark rationaleforusingcentralizedtransductioninhibitionassaysinthreephase3raavgenetherapyclinicaltrials AT wilcoxlisa rationaleforusingcentralizedtransductioninhibitionassaysinthreephase3raavgenetherapyclinicaltrials AT winburnian rationaleforusingcentralizedtransductioninhibitionassaysinthreephase3raavgenetherapyclinicaltrials AT somanathansuryanarayan rationaleforusingcentralizedtransductioninhibitionassaysinthreephase3raavgenetherapyclinicaltrials |